The Future of Biobanks: Regulation, ethics, investment and the humanization of drug discovery

Published by	Business Insights
Published	March, 2009	Product code	84803
Content info	129 pages
Price	US $ 3835 PDF by E-mail (Single User License) US $ 14381 PDF by E-mail (Global Site License)

Introduction
Related Reports

The Future of Biobanks: Regulation, ethics, investment and the humanization of drug discovery published by Business Insights in March, 2009. This report consists of 129 pages and the price starts from US $ 3835.

Introduction

Abstract

Biobanks collect and store human biospecimens, playing a vital role in the development of novel drugs and diagnostics. In recent years, large population-based biobanks have been established which monitor the health status of participants over time to assess the natural occurrence and progression of common diseases. Hundreds of disease-based biobanks are located around the world, which are a valuable resource for biomarker discovery as well as for studying progression, mortality and responses to treatment. - The Future of Biobanks - is a new report published by Business Insights that examines major trends in the biobanking industry and identifies the key initiatives to upgrade the biobanking infrastructure. This report explores the applications of biobanks and provides examples of how large sets of high-quality biosamples are creating new ways to diagnose, prevent and treat diseases. The activities of over 180 US biobanks are assessed to illustrate how the scale and scope of biobanking is changing. This report also evaluates the limitations of biobanks, in addition to reviewing the unique legal, regulatory and ethical issues that surround this new frontier of biomolecular research.

The Future of Biobanks Executive summary Overview Biobanking trends Population-based biobanks Disease-based biobanks Private-sector biobanks Regulatory and ethical issues

Chapter 1 Overview

Summary
Introduction
Definition of biobanks
Historical context
Scientific and commercial relevance of biobanks
Targeted therapeutics
Diagnostic and prognostic tests
Drug development
Disease etiology
Future outlook

Chapter 2 Trends in biobanking

Introduction
Introduction
The limitations of biobanks
Initiatives to improve biobanks
Sample variability
Sample quality
Older biobanks
Modern biobanks
Biobanking costs
Increasing harmonization
Future outlook

Chapter 3 Population-based biobanks

Introduction
Introduction
Types of population biobanks
Cohort studies
Founder population biobanks
- deCODE Genetics
- CARTaGENE
- Genizon Biosciences
- Jurilab
National population biobanks
- UK Biobank
- LifeGene
- Estonian biobank
- Latvian biobank
- Canadian Partnership for Tomorrow Project
- Other national biobanks
Future outlook

Chapter 4 Disease-based biobanks

Introduction
Introduction
Growth in disease-based biobanks
- Cancer biobanks
- Other diseases
Healthy sample biobanks
Collaborative networks
- onCORE UK
- International Genomics Consortium
- Cancer Genome Atlas
- Future outlook

Chapter 5 Private-sector biobanks

Introduction
Introduction
Licensed biobanks in the UK
Contract service providers
Biomarker discovery companies
Pharmaceutical collections
Research collaborations
Clinical trials
Future outlook

Chapter 6 Regulatory and ethical issues

Summary
Introduction
Current regulatory framework
Informed consent
Withdrawal and ownership
Confidentiality
Commercialization
Future outlook

Appendix

Methodology
Index

List of Figures

Figure 1.1: Cumulative number of DNA samples banked in population-based studies*, 1970-2009
Figure 1.2: NIH sponsored clinical trials conducting gene expression profiling, 2000-08
Figure 2.1: Geographical distribution of biobanks
Figure 2.2: Drivers and resistors
Figure 2.3: The evolution of biobanks
Figure 4.1: Number of diseases-based biobanks, by therapy area, US 1995-2008
Figure 5.1: Establishments licensed to operate biobanks, by sector, England, Wales and Northern Ireland, 2008
Figure 5.2: Examples of private-sector biobanks